News - GlaxoSmithKline, Management

Filter

Current filters:

GlaxoSmithKlineManagement

Popular Filters

Report: Health care companies lead the way in corporate compliance

27-12-2013

Health care companies are leading the way in terms of public trust and transparency, according to The…

AstraZenecaGlaxoSmithKlineLegalManagementPharmaceuticalReckitt BenckiserUK

GlaxoSmithKline to ditch sales target-based compensation, change other global marketing practices

GlaxoSmithKline to ditch sales target-based compensation, change other global marketing practices

17-12-2013

In the wake of the bribery scandal in China, as well as a record-breaking $3 billion fine in the USA…

GlaxoSmithKlineGlobalManagementMarkets & MarketingPharmaceutical

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

GlaxoSmithKline could be considering quitting China, says BBC editor

06-09-2013

For most multinational companies, it is a no-brainer that they have to be big in China, if their global…

Asia-PacificGlaxoSmithKlineLegalManagementMarkets & MarketingPharmaceutical

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir

18-02-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Knighthood for GlaxoSmithKline’s Andrew Witty; Teva succession plan

03-01-2012

Andrew Witty, chief executive of UK drug giant GlaxoSmithKline (LSE: GSK) has been awarded a Knighthood…

GenericsGlaxoSmithKlineManagementPharmaceuticalTeva Pharmaceutical Industries

Dendreon to slash 25% of work force under restructuring plan; updates on Provenge

12-09-2011

US biotech firm Dendreon (Nasdaq: DNDN), which last month scaled back expectations for its novel prostate…

BiotechnologyDendreonFinancialGlaxoSmithKlineManagementOncologyPharmaceuticalProvenge

Back to top